Multiple myeloma is a universally fatal disease characterized by the accumulation of malignant plasma cells in the bone marrow. The growth characteristics of myeloma cells are in striking contrast with those of normal end-stage plasma cells. The molecular regulation of normal B cell terminal differentiation is incompletely understood, however, it is believed that this regulation involves the activation of transcription factors that are necessary to drive expression of genes whose products are specific to the differentiated phenotype. Interleukin 6 (IL-6) is an important example of an external signal that drives normal B cell differentiation; however, it does so in the absence of any effect on cell growth. In contrast, IL-6 functions as a potent growth factor for malignant plasma cells in patients with aggressive myeloma. We have, therefore, hypothesized that myeloma cells display an altered responsiveness to IL-6, i.e., growth rather than differentiation, and as a result of this IL-6 responsiveness, there are key changes in IL-6-stimulated gene expression. Considerable information exists regarding IL-6-mediated activation of the JAK/STAT and Ras-MAP kinase (Ras-MAPK) pathways, however, the role of either pathway has not been established in IL-6 mediated myeloma cell growth. The Pi previously has established a panel of IL-6-responsive human myeloma cell lines and also has significant expertise in the study of normal human B cells and plasmablasts. She is, therefore, uniquely positioned to analyze the role of these well-characterized signaling pathways in myeloma cell growth.
The specific aims i nclude: (l) to determine the importance of the JAK/STAT activation pathway in IL-6 driven myeloma cell proliferation; (2) to determine the importance of the Ras/MAPK activation pathway in IL-6 driven myeloma cell proliferation; and (3) to identify and characterize the genetic targets of IL-6 signal transduction pathway(s) in myeloma by utilizing differential display reverse transcription polymerase chain reaction and cDNA array analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA062242-06
Application #
6300458
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2000-02-14
Project End
2001-01-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lwin, S T; Fowler, J A; Drake, M T et al. (2017) A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo. Mol Cancer 16:49
Gonsalves, W I; Rajkumar, S V; Dispenzieri, A et al. (2017) Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia 31:130-135
Mullikin, Trey C; Rajkumar, S Vincent; Dispenzieri, Angela et al. (2016) Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol 91:473-5
Gonsalves, Wilson I; Timm, Michael M; Rajkumar, S Vincent et al. (2016) The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leuk Res 44:32-9
Kaufman, Gregory P; Dispenzieri, Angela; Gertz, Morie A et al. (2015) Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol 90:181-6
Gonsalves, W I; Leung, N; Rajkumar, S V et al. (2015) Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 5:e296
Cesarman-Maus, Gabriela; Braggio, Esteban; Lome-Maldonado, Carmen et al. (2014) Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb Res 133:606-9
Landgren, O; Graubard, B I; Katzmann, J A et al. (2014) Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 28:1537-42
Kumar, S K; Dispenzieri, A; Lacy, M Q et al. (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122-8
Gonsalves, Wilson I; Rajkumar, S Vincent; Go, Ronald S et al. (2014) Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 124:907-12

Showing the most recent 10 out of 365 publications